Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Drugmaker Eli Lilly and Company has hired Sandy Rodriguez as SVP and chief communications officer, effective on June 9. Rodriguez will report to Jennifer Oleksiw, SVP and global chief customer officer ...

Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP ...

Pharmaceutical manufacturing giant Eli Lilly and Co. is exploring potential economic incentives for a $5.9B biomanufacturing ...

Pharma giant Eli Lilly is planning a $5.9 billion investment for a massive pharmaceutical manufacturing facility in McCord ...